Trilipix plus Crestor improves lipid targets

Data presented at the American College of Cardiology annual meeting in Florida, show that US health care major Abbott Laboratories' Trilipix  (fenofibric acid) delayed-release capsules plus AstraZeneca's Crestor  (rosuvastatin) met all of the study's primary endpoints. Trilipix 135mg  plus Crestor 5mg significantly improved high-density lipoprotein  cholesterol and triglycerides versus Crestor 5mg alone and significantly  improved LDL cholesterol compared to Trilipix 135mg alone in patients  with lipid problems.

"More comprehensive treatment is often needed in certain patients with  mixed dyslipidemia to help reach targets for all three key lipids," said  Eli Roth, from the USA's University of Cincinnati College of Medicine.  "The results from this study are encouraging because Trilipix combined  with the lowest available dose of Crestor improved LDL, HDL and  triglycerides," he added.

Trilipix is the first and only fibrate to be approved for use in  combination with a statin. In certain patients, treatment guidelines  recommend the combination of a fibrate with a statin to improve lipid  levels, Abbott noted.